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Abstract
Objectives This study reports on the rapid isolation of verbascoside from Lippia citri-
odora H.B.K. (Verbenaceae), an inexpensive and widespread source, and the evaluation of
its antihyperalgesic activity.
Methods Isolation of verbascoside was achieved by size exclusion chromatography with
Sephadex LH-20 eluting with 50% EtOH, which is proposed as a fast and efficient method
of separation.
Key findings The antihyperalgesic activity of verbascoside was tested by in-vivo assay
using the paw-pressure test in two animal models of neuropathic pain: a peripheral monon-
europathy produced either by a chronic constriction injury of the sciatic nerve (CCI) or by
an intra-articular injection of sodium monoiodoacetate (MIA).
Conclusions Verbascoside administered intraperitoneally at a dose of 100 mg/kg reverted
the mechanical hyperalgesia in both CCI and MIA treated rats, as evaluated in the paw-
pressure test. Verbascoside was also effective against mechanical hyperalgesia after oral
administration at doses of 300 and 600 mg/kg.
Keywords antihyperalgesic; Lippia citriodora; neuropathic pain; paw-pressure test;
verbascoside
Introduction
Verbascoside (acteoside, Figure 1) is a phenylpropanoid glycoside isolated from several
medicinal plants of different families such as Verbenaceae, Oleaceae, Buddlejaceae, Lami-
aceae and Scrophulariaceae,[1,2] including plants used in Traditional Chinese Medicine.[3] The
literature regarding the biological activity of this compound is extensive: anti-inflammatory,
anti-ulcerogenic and antispasmodic activity,[2,4–8] antiproliferative properties and inhibition
of telomerase,[9,10] immunomodulatory,[11] antioxidant, photoprotective[12–14] and analgesic
activity[15–17] have all been reported. Nevertheless, to the best of our knowledge, no data are
available on the activity of verbascoside against neuropathic pain, a widespread disorder
induced by autoimmune diseases, drugs or toxin exposure, infections, metabolic insults or
trauma. Typically, neuropathic pain is depicted by nerve damage, which causes muscle
weakness, altered functionality and sensitivity, and a chronic pain syndrome characterized
by allodynia (pain elicited by a non-noxious stimulus) and hyperalgesia (increased
pain response to a noxious stimulus), which can persist for a long time after the initial injury
is resolved.[18] The underlying molecular mechanisms of neuropathic pain are still not
completely understood, and treatment is still unsatisfactory in most cases.[19] Thus, there is
an urgent need to develop novel therapeutics for the effective treatment of neuropathic
pain.
In this study, the rapid isolation of verbascoside from Lippia citriodora H.B.K. (Verben-
aceae), a widespread and inexpensive source, is reported, and its antihyperalgesic activity
was tested in vivo. The assays were carried out using the paw-pressure test[20] in two animal
models of neuropathic pain where a peripheral mononeuropathy was produced either by a
chronic constriction injury of the sciatic nerve (CCI)[21] or by an intra-articular injection of
sodium monoiodoacetate (MIA).[22]
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Materials and Methods
Chemicals
Ethanol, analytical reagent grade, was from Riedel-de
Haen (Seelze, Germany). All solvents used were of high-
performance liquid chromatography (HPLC) grade; CH3CN
and MeOH for HPLC were purchased from Merck (Darmstadt,
Germany). HCOOH (85%) was provided by Carlo Erba
(Milan, Italy). Water was purified by a Milli-Qplus system
from Millipore (Milford, MA, USA). Carboxymethylcellulose
sodium salt was from Fluka Chemie GmbH (Steinheim,
Germany). NaCl 0.9% solution was from Fresenius Kabi Italia
spa (Isola della Scala, Verona, Italy). Naloxone hydrochloride
(>99%), tramadol (>99%) and ketorolac (99%) were from
Sigma (St Louis, MA, USA). Morphine hydrochloride (>99%)
was from S.A.L.A.R.S spa (Como, Italy). Pregabalin (>99%)
was purchased from Chem Pacific (Baltimore, MD, USA).
Plant material
Commercial dried leaves of cultivated L. citriodora H.B.K.
(Verbenaceae) harvested in 2004 were obtained from Aboca
(Pistrino di Citerna, Perugia, Italy; lot no. 4L0466) and used
for the isolation of verbascoside.
Isolation of verbascoside
A total of 500 g of herbal drug was exhaustively extracted
with a hydroalcoholic solution (EtOH 80%) by maceration.
This solution was concentrated to dryness in a rotavapor
under reduced pressure and controlled temperature (30°C),
and then lyophilised, giving 34.75 g of dried extract (6.96%
with respect to the herbal drug). A total of 5 g of the extract
(containing ~12% of verbascoside as determined by HPLC/
diode array detection (DAD)/electrospray ionization mass
spectrometry (ESI MS)) was dissolved in 5 ml EtOH 50% and
purified by size exclusion chromatography using Sephadex
LH-20 (Amersham Biosciences AB, Uppsala, Sweden)
column chromatography (length 50 cm, diameter 4 cm) and
EtOH 50% as the mobile phase. Fractions were analysed by
thin layer chromatography (plates of silica gel 60 F254;
Merck, Damstatt Germany; solvent CHCl3/MeOH 7 : 3) using
vanillin sulfuric reagent. Verbascoside (700 mg) was purified
from the extract with a purity of 81.2% assessed by HPLC/
DAD/ESI MS analysis using verbascoside reference
standard (purity 98% by HPLC/DAD/ESI MS, gas chroma-
tography and nuclear magnetic resonance). Verbascoside
was re-crystallised from MeOH to obtain pure compound
(510 mg, purity >98%). Purification of verbascoside from
the extract was repeated six times to obtain enough pure
verbascoside.
Analytical HPLC/DAD characterisation
The HPLC system consisted of a HP 1100 L instrument with
a diode array detector and was managed by a HP 9000 work-
station (Agilent Technologies, Palo Alto, CA, USA). The
column was a Varian Polaris TM C18-E (250 mm ¥ 4.6 mm
i.d., 5 micron) maintained at 26°C with a pre-column of the
same phase. The eluents were H2O at pH 3.2 (by formic acid,
A) and acetonitrile (B). The following multistep linear gradi-
ent was applied: from 87% A to 85% A in 10 min, to 75% B
in 10 min and then a plateau for 3 min; 2 min to 95% CH3CN
and a final plateau of 3 min. The total time of analysis was
28 min, the equilibration time was 10 min, the flow rate was
0.8 ml/min, the injection volume was 10 ml and the oven tem-
perature 26°C. The UV-Vis spectra were recorded between
220 and 500 nm, and the chromatographic profiles were reg-
istered at 240, 330 and 350 nm.
Analytical HPLC/ESI MS characterisation
The HPLC system described above was interfaced with a
HP 1100 MSD API-electrospray (Agilent Technologies, Palo
Alto, CA, USA). The interface geometry, with an orthogonal
position of the nebulizer with respect to the capillary inlet,
allowed use of analytical conditions similar to those used for
HPLC/DAD analysis in order to achieve the maximum sen-
sitivity of ESI values. The same column, time period and flow
rate were used during the HPLC/ESI MS analyses. Mass
spectrometry operating conditions were optimised in order to
achieve maximum sensitivity values: negative and positive
ionisation mode, scan spectra from m/Z 100 to 800, gas tem-
perature of 350°C, nitrogen flow rate of 10 l/min, nebulizer
pressure 30 psi, quadrupole temperature 30°C, and capillary
voltage 3500 V. The applied fragmentors were over the range
80–180 V. Identification of constituents was carried out by
HPLC/DAD and HPLC/ESI MS analysis, and/or by compari-
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Figure 1 Chemical structure of verbascoside.
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son and combination of their retention times, UV-Vis and
mass spectra of the peaks with those of authentic standards
when possible, isolated compounds or characterised extracts,
as well as literature data.
In-vivo tests
Male Sprague-Dawley albino rats (180–200 g) from Harlan
(S. Piero al Natisone, Italy) were used. Four rats were housed
per cage and the cages were placed in the experimental room
24 h before the test for acclimatisation. The animals were fed
a standard laboratory diet and tap water ad libitum, and were
kept at 23  1°C with a 12-h light–dark cycle (lights on at
0700 hours). The experiments were performed in accordance
with the European Communities Council directive 86/609/
EEC) and were approved by the Ethics Committee of our
institution. All efforts were made to minimize the number and
suffering of the animals used.
Application of test substances
Drugs were dissolved in isotonic (NaCl 0.9%) saline solution
or dispersed in carboxymethylcellulose sodium 1% solution
immediately before use. Doses ranged from 10 to 600 mg/kg
and the dose–response curve allowed determination of the
active doses for both intraperitoneal and oral administration.
Drug concentrations were prepared and administered in a
volume of 10 ml/kg for both administration routes.
Chronic constriction injury
A peripheral mononeuropathy was produced in adult rats by
placing loosely constrictive ligatures around the common
sciatic nerve according to the method described by Bennett
and Xie.[21] Rats were anaesthetised with chloral hydrate.
The common sciatic nerve was exposed at the level of the
middle of the thigh by blunt dissection through the biceps
femoris. Proximal to the sciatica trifurcation, about 1 cm of
the nerve was freed of adhering tissue and four ligatures (3/0
silk tread) were tied loosely around it with about 1 mm
spacing. The length of the nerve thus affected was 4–5 mm
long. Great care was taken to tie the ligatures such that the
diameter of the nerve was seen to be just barely constricted
when viewed with 40¥ magnification. In every animal, an
identical dissection was performed on the opposite side
except that the sciatic nerve was not ligated. The left paw
was untouched.
Monoiodioacetate injection
Joint damage was induced by a single intra-articular injection
of 2 mg of sodium monoiodioacetate into the left knee joint
of anaesthetised rats in a total volume of 25 ml. The dose of
monoiodoacetate was chosen based on a previous literature
report[22] and in-house dose–response data using 0.5, 1 and
2 mg monoiodoacetate.
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Figure 2 Chromatographic profiles at 240, 330 and 350 nm of the hydroalcoholic extract of Lippia citriodora H.B.K. I1, hastatoside; I2, verbenalin;
Ph1, b-OH verbascoside; Ph2, b-OH isoverbascoside; Ph3, verbascoside; Ph4, isoverbascoside; Ph5, eukovoside or isomer; Ph6, eukovoside or isomer;
Ph7, eukovoside or isomer; Fl1, luteolin-7-O-diglucuronide; Fl2, apigenin-7-O-diglucuronide; Fl3, luteolin-7-O-glucuronide; Fl4, apigenin-7-O-
glucuronide.
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Paw-pressure test
The Randall and Selitto instrument (Ugo Basile, Comerio,
VA, Italy) exerts a force that is applied at a constant rate
(32 g/s) with a cone-shaped pusher on the upper surface of the
rat hind paw. The force is continuously monitored by a pointer
moving along a linear scale. The pain threshold was deter-
mined by the force that induced the first struggling by the rat.
An arbitrary cut-off value of 250 g was adopted. Those mice
scoring less than 40 g or over 75 g in the pretest were rejected
(25%). The pain threshold was measured before (pretest) and
at 15, 30 and 45 min after the beginning of the test.
Rota-rod test
The rota-rod apparatus (Ugo Basile, Comerio, VA, Italy) con-
sisted of a base platform and a rotating rod with a diameter of
3 cm and a non-slippery surface. The rod was placed at a height
of 15 cm from the base. The rod, 30 cm in length, was divided
into five equal sections by six disks. Thus, up to five rats were
tested simultaneously on the apparatus, with a rod-rotating
speed of 16 rev/min. The integrity of motor coordination was
assessed on the basis of the number of falls from the rod in 30 s.
Those mice scoring less than three and more than six falls in
the pretest were rejected (20%). The performance time was
measured before (pretest) and at 15, 30 and 45 min after the
beginning of the test. A total of 4–5 rats per group were tested.
Statistics
All experimental results are given as the mean  SEM.
Analysis of variance followed by Fisher’s protected least sig-
nificant difference procedure for post-hoc comparison were
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Figure 3 Effect of intraperitoneal administration of verbascoside in the rat paw-pressure test. Verbascoside was administered intraperitoneally in two
animal models of neuropathic pain where a peripheral mononeuropathy was produced by either a chronic constriction injury of the sciatic nerve (CCI)
(a) or by an intra-articular injection of sodium monoiodoacetate (MIA) (b).
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used to verify the significance of differences between two
means. Data were analysed with StatView software (The
MacIntosh Company, Hilliard, OH, USA) for the Macintosh.
P values of less than 0.05 were considered significant.
Results and Discussion
Commercial dried plant material was exhaustively extracted
with hydroalcoholic solution (EtOH 80%). The macerates
were filtered, evaporated under reduced pressure and lyo-
philized to obtain a dried extract which was analysed by
HPLC/DAD/ESI MS. The presence of verbascoside in the
extract was assessed by comparison of its retention time (tR)
with the authentic sample verbascoside international standard
and it was confirmed by UV and MS data (Figure 2). Verbas-
coside resulted in about 12% of the dried extract calculated
using an international standard. Verbascoside was purified by
size exclusion chromatography using Sephadex LH-20 and
eluting with ethanol (50%). Verbascoside was crystallised
with methanol to obtain a purity of >98%, determined by
HPLC/DAD/ESI MS and confirmed by nuclear magnetic
resonance. Size exclusion chromatography is proposed as a
rapid and easily applied method at the industrial scale. This
method enabled fast and efficient isolation and purification
of verbascoside, recovering more than 85% of the constituent
present in the crude dried extract. The advantages of this
method include high recovery of the target product, short and
well defined separation times, narrow bands which lead to
good sensitivity, freedom from sample loss because solutes do
not interact with stationary phase, and the possibility to use
ecologically friendly solvents.
Neuropathic pain is characterised by nerve damage that
causes a chronic pain syndrome characterized by allodynia
and hyperalgesia. The antiallodynic effect was quantified by
the von Frey filament test and has been reported elsewhere.[23]
In this study, we measured the effect of verbascoside on
hyperalgesia which is the component of neuropathic pain
that can persist for a long time after the initial injury is
resolved.[18] The antihyperalgesic activity of pure verbasco-
side was investigated in animal models of neuropathic pain
(a)
(b) 
after treatment
∗ ∗
∗
before 
treatment
∗
∗
∗
∗
∗
∗ ∗
0
20
40
60
80
100
0 15 30 45 60
CMC 
CMC operated (CCI)
verbascoside 300 mg/kg p.o.
verbascoside 600 mg/kg p.o.
0
20
40
60
80
100
0 15 30 45 60
CMC
MIA
verbascoside 300 mg/kg p.o.
verbascoside 600 mg/kg p.o.
after treatment
Time (min)
Time (min)
∗
∗
before 
treatment
∗
∗
∗
∗ ∗
∗
W
ei
gh
t (
g)
W
ei
gh
t (
g)
Figure 4 Effect of oral administration of verbascoside in the rat paw-pressure test. Verbascoside was administered orally in two animal models of
neuropathic pain where a peripheral mononeuropathy was produced by either in a chronic constriction injury of the sciatic nerve (CCI) (a) or by an
intra-articular injection of sodium monoiodoacetate (MIA) (b). CMC, carboxymethylcellulose sodium salt.
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(CCI) and of peripheral neuropathic pain (MIA). The paw
withdrawal threshold was measured using a Randall and
Selitto apparatus exerting a force that increases at constant
rate (32 g/s). The stimulus at which the rats withdrew the
paw was recorded before treatment and after drug admi-
nistration at different times (15, 30, 45 and 60 min). The
results represent means  SEM of the mechanical threshold
expressed as grams. Tests were performed using increasing
doses of verbascoside ranging from 10 to 600 mg/kg. A dose
of 100 mg/kg was selected for the intraperitoneal injection
and 300 mg/kg for the oral administration because these doses
showed the best in-vivo performances to reduce hyperalgesia.
Verbascoside when administered intraperitoneally at a
dose of 100 mg/kg reverted the mechanical hyperalgesia, as
evaluated in the paw-pressure test, in CCI rats (Figure 3a).
The antihyperalgesic effect started 15 min after administra-
tion and persisted up to 45 min. In the case of MIA treated rats
(Figure 3b), verbascoside administered intraperitoneally at
the same dose of 100 mg/kg was active against secondary
hyperalgesia 15 min after administration and persisted up to
30 min.
Verbascoside was also effective against mechanical
hyperalgesia after oral administration. At doses of 300 and
600 mg/kg it reverted the hyperalgesia induced by CCI
(Figure 4a) and the secondary hyperalgesia induced by MIA
injection with a long-lasting effect (Figure 4b): the antihype-
ralgesic effect started 15 after administration and it was still
significant at 60 min. The positive controls used as reference
compounds are reported in Figure 5.
Verbascoside was unable to increase the pain threshold in
naïve animals, showing the lack of any analgesic activity at
intraperitoneal doses of 50 and 100 mg/kg (Figure 6a) as well
as oral doses of 300 and 600 mg/kg (Figure 6b). Therefore the
antihyperalgesic activity of verbascoside as a consequence of
its analgesic properties can be excluded. Analgesic activity of
verbascoside has been reported when administered orally and
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Figure 5 Positive controls used as reference compounds in two animal models of neuropathic pain. Peripheral mononeuropathy was produced by
either a chronic constriction injury of the sciatic nerve (CCI) (a) or by an intra-articular injection of sodium monoiodoacetate (MIA) (b).
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topically in other tests such as writhing and tail-flick assays,[15]
where different pathological mechanisms are involved.
The antihyperalgesic effect of verbascoside was not pre-
vented by pretreatment with the opioid antagonist naloxone,
suggesting that verbascoside does not require the activation of
the opioid system to reverse hyperalgesia (data not shown).
The safety of verbascoside was also established by the
rota-rod test: it did not modify gross behaviour of the animals
at the highest effective doses. The rota-rod test was also used
to reveal any alterations of motor coordination induced by the
investigated compound. The number of falls from the rotating
rod showed the lack of any impairment in the motor coordi-
nation of animals treated with verbascoside in comparison
with the control group, ruling out the possibility that the
results obtained were due to altered viability of the animals.
During each session, the number of falls of mice with unal-
tered locomotor activity decreased as the animals learned how
to balance on the rotating rod (Table 1).
Conclusions
Despite the large number of approved analgesics such as
opioids and nonsteroidal anti-inflammatory drugs, the treat-
ment of neuropathic pain or peripheral neuropathic pain is
often hampered by poor activity of the available drugs and the
occurrence of adverse drug reactions.[24] The current pharma-
cological treatment of neuropathic pain includes tricyclic anti-
depressants, anticonvulsants, serotonin-reuptake inhibitors
and opioids. However, all of these drugs have limited efficacy
combined with a number of side-effects, and the mechanism
of how they relieve pain is not fully elucidated. The present
findings illustrate the antihyperalgesic properties of the
natural compound verbascoside and may help in the develop-
ment of a new therapeutic strategy for neuropathic pain, par-
ticularly in view of its excellent safety profile. The relatively
high doses used for both intraperitoneal and oral administra-
tion in this study could be related to low bioavailability of this
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Figure 6 Lack of analgesic activity of verbascoside in the rat paw-pressure test. At interperitoneal doses of 50 and 100 mg/kg (a) as well as oral doses
of 300 and 600 mg/kg (b) verbascoside showed a lack of any analgesic activity in the paw-pressure test.
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molecule possibly due to very high water solubility and
limited hydrophobic properties. Future investigation of its
pharmacokinetic behaviour and the introduction of appropri-
ate formulations could lead to a noticeable decrease in the
active dose of verbascoside.
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Table 1 Lack of effect of verbascoside in the rota-rod test
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(mg/kg p.o.)
Before
treatment
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Carboxymethylcellulose sodium salt – 3.6 0.3 2.2 0.4 1.9 0.3 1.2 0.3
Verbascoside 1000 3.9 0.4 2.5 0.3 2.1 0.3 0.7 0.2
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